^
Association details:
| Biomarker: | CD20 expression |
|---|---|
| Cancer: | Non-Hodgkin’s Lymphoma |
| Drug: | Ordspono (odronextamab) (CD20 inhibitor, CD3 agonist) |
| Direction: | Resistant |
Evidence:
Source:
Title:
2108 Baseline Biomarkers of T-Cell Function Correlate with Clinical Responses to Odronextamab (REGN1979), and Loss of CD20 Target Antigen Expression Identified As a Mechanism of Treatment Resistance
Published date:
11/04/2020
Excerpt:
Single-cell analysis of a fresh tissue sample from a case of progressive disease, occurring after a prior complete response, showed a complete loss of CD20 expression on the cell surface while maintaining abundant tumor-infiltrating effector T cells.
